Temperature-sensitive embolic agent during chemoembolization for primary liver cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, multicenter, randomized, parallel-controlled, non-inferiority trial in China with a lead-in phase followed by a main study enrolling about 216 subjects. Participants are randomly assigned 1:1 to receive transcatheter arterial chemoembolization (TACE) with anthracycline and iodized oil combined with either a temperature-sensitive tumor embolic agent (test) or gelatin sponge particles (control). The main efficacy endpoint is disease control rate by mRECIST, capturing complete responses, partial responses, and stable disease. Safety and tumor response will be compared between groups to determine whether the thermosensitive agent performs at least as well as the standard embolic material.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1\) Aged 18 to 80 (inclusive), of either gender;
* 2\) Subjects who have been diagnosed with hepatocellular carcinoma (pathologically or clinically) according to the diagnostic criteria in the "Diagnosis and Treatment Guidelines for Primary Liver Cancer (2024 Edition)" and require TACE treatment;
* 3\) Subjects with stage Ⅱb and Ⅲa liver cancer according to the Chinese Liver Cancer Staging Classification (CNLC), as well as subjects with stage Ⅰa, Ⅰb, and Ⅱa liver cancer who are not suitable/willing for surgical resection, liver transplantation, and ablation therapy;
* 4\) Subjects with at least one untreated intrahepatic tumor lesion (maximum diameter ≤10cm) that meets the mRECIST definition (diameter ≥1cm);
* 5\) The subjects agree to participate in this study and sign the informed consent form.

Exclusion Criteria:

* 1\) Subjects whose target lesions have undergone local treatment (including but not limited to surgery, TACE, radiotherapy, hepatic artery infusion, ablation, etc.), or subjects whose target lesions require ablation/radiotherapy in combination with TACE treatment at the time of enrollment;
* 2\) Subjects whose blood routine test results meet the following criteria: white blood cell count \<3.0×10\^9/L; platelet count \<50×10\^9/L, and this condition cannot be corrected (excluding subjects with hypersplenism or chemotherapy-induced bone marrow suppression);
* 3\) Renal dysfunction: serum creatinine \>176.8 μmol/L or creatinine clearance rate \< 30 ml/min;
* 4\) Uncorrectable coagulation dysfunction;
* 5\) Uncorrectable hypercalcemia and respiratory acidosis;
* 6\) Patients with systemic cachexia or multiple organ failure;
* 7\) Patients with severe infections that cannot be effectively controlled and are not suitable for TACE treatment;
* 8\) Complete obstruction of the main portal vein, insufficient collateral compensation of the portal vein, and inability to restore portal venous blood flow to the liver through portal veinoplasty;
* 9\) Known contraindications or allergies to anthracycline chemotherapeutic drugs, calcium chloride injection, contrast media, and embolic materials;
* 10\) Patients who are currently using cardiac glycosides;
* 11\) Patients with target lesions who are at risk of ectopic embolism in the feeding artery (such as vascular access endangering normal areas, uncorrectable arteriovenous fistulas, and portal vein fistulas) or anatomical abnormalities that make them unsuitable for interventional procedures;
* 12\) Patients who have been diagnosed with other malignant tumors within 2 years before randomization (except for basal cell or squamous cell skin cancer, cervical or breast carcinoma in situ that have been resected radically);
* 13\) Patients with diffuse or distant extensive metastasis of tumors, with an expected survival time of less than 90 days;
* 14\) Pregnant/lactating women, or those who have family planning;
* 15\) Subjects who have participated in other drug or medical device intervention clinical trials within 30 days before randomization;
* 16\) Other subjects who were considered unsuitable for participation in this clinical trial by the researchers.

Where it's running

• Anhui Provincial Hospital
  Hefei, Anhui, China Recruiting
• Peking University First Hospital
  Beijing, Beijing Municipality, China Recruiting
• Affiliated Cancer Hospital of Guangxi Medical University
  Nanning, Guangxi, China Recruiting
• The Affiliated Cancer Hospital of Guizhou Medical University
  Guiyang, Guizhou, China Recruiting
• The Fourth Hospital of Hebei Medical University (Hebei Provincial Cancer Hospital)
  Shijiazhuang, Hebei, China Recruiting
• Anyang Tumor Hospital
  Anyang, Henan, China Recruiting

Study contacts

• Study coordinator: Huamin Wang
• Email: huaminwang@grandpharma.cn
• Phone: +86 15116996413

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Integrated genomic and clinical database for cancer biomarker discovery

  Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.

  Recruiting Samsung Medical Center · Seoul, Gang-Nam · NCT07911267

• BGB-B2033 vs Sorafenib or Lenvatinib for advanced liver cancer

  This study tests whether the investigational drug BGB-B2033 can help people with advanced hepatocellular carcinoma when given after prior PD-1/PD-L1 therapy, compared with the standard medicines sorafenib or lenvatinib.

  Recruiting at 2 sites Phase 3 BeOne Medicines · South Brisbane, Queensland and 1 other locations · NCT07836530

• Protoacoustic Imaging to See Radiation Delivery in Proton Therapy

  This study tests radioacoustic imaging with ultrasound to help doctors see where proton therapy is delivering radiation for liver and prostate cancer patients.

  Recruiting University of Oklahoma · Oklahoma City, Oklahoma · NCT07832617

• YMN-136 vaccine for advanced liver, biliary tract, and pancreatic cancers

  A first-in-human dose-escalation study tests whether the YMN-136 vaccine is safe and tolerable for adults with unresectable advanced liver, biliary tract, or pancreatic cancers who have progressed on standard therapies or cannot receive them.

  Recruiting Phase 1 West China Hospital · Chengdu, Sichuan · NCT07763301

• DRAGON: International registry for patients who had combined portal and hepatic vein embolization before liver surgery

  This registry collects data on patients who had PVE/HVE before liver resection to see if it helps liver regeneration and what factors relate to outcomes.

  Recruiting at 30 sites Maastricht University Medical Center · Chicago, Illinois and 30 other locations · NCT07717437

• Precision navigation to boost cancer screening participation in high-risk communities

  This study tests whether a personalized navigation program helps adults aged 45–74 in Chinese communities who are at high risk for several cancers to complete recommended free cancer screenings.

  Recruiting at 3 sites Hunan Cancer Hospital · Huaihua, Hunan and 2 other locations · NCT07676383

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.